The new and improved Spring 2018 edition of Pharmafile is available to read online now!

pharmafile | May 9, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CNS, Cancer, Pharmafocus, cardiovascular, cvd, oncology, pharmafile 

The Spring 2018 edition of Pharmafile, our long-running bi-annual guide to the latest trends, projections and thought leadership positions in the pharmaceutical and life sciences industries, is now available to read online.

In this new revamped edition, Pharmafile now centres on three specially selected therapeutic areas. The first run of this new format focuses on oncology, cardiovascular disorders and central nervous system disorders.  

By far the most central and dynamic field within the industry today is oncology, an area that is hugely significant on a personal level to so many worldwide. It’s no wonder that this has been met by a comparable level of investment – the market is expected to break a massive $150 billion by 2020.

While perhaps not as emotive an area as oncology, CVD remains the single biggest cause of death globally, killing 17.7 million in 2015 alone, and is linked to a number of prevalent conditions which greatly increase risk of adverse events, such as the obesity epidemic and diabetes. The space is forecast to exceed $146 billion by 2022.

Finally, a varied and challenging space, CNS disorders affect many individuals either directly or otherwise, and as populations continue to live longer around the world, the threat of conditions such as dementia continue to increase, often outpacing our understanding and ability to effectively treat them. The space has seen tough times recently, as major industry players withdraw their investment, yet the CNS market is expected to plough forward to edge close to $129 billion by 2025.

Inside, you can find a wealth of market reports, thought pieces and interviews with key industry figures within these three crucial areas. Read the online edition of Pharmafile Spring 2018 now!

Matt Fellows

Related Content

AstraZeneca and MSD’s Lynparza receives NICE positive recommendation as a cancer maintenance treatment

UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence …


Innate Pharma announces drug researched with Sanofi receives FDA Fast Track Designation

Innate Pharma has announced that the drug jointly researched between itself and Sanofi has received US …


GRAIL and University of Oxford showcase first prospective study results for multi-cancer early detection test

US-based healthcare company GRAIL and the University of Oxford, UK, have announced encouraging first prospective …

Latest content